Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2639-2646

  Colao, Annamaria ^a   Pivonello, Rosario ^a   Galderisi, Maurizio ^a   Cappabianca, Paolo ^a   Auriemma, Renata S ^a   Galdiero, Mariano ^a   Cavallo, Luigi M ^a   Esposito, Felice ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGE; ARTICLE; ATRIAL MITRAL FLOW VELOCITY; CARDIOMYOPATHY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GENDER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPOPHYSIS FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLE; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

EID: 47549113650     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0299     Document Type: Article

References (42)

1. Colao A, Lombardi G 1998 Growth hormone and prolactin excess. Lancet 352:1455-1461
2. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE, the United Kingdom Acromegaly Study Group 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 83:2730-2734
3. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
4. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
5. Holdaway IM, Rajasoorya CR, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
6. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617
7. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
8. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
9. Kreutzer J, Vance ML, Lopes MB, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4027
10. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407-413
11. Ahmed S, Elsheikh M, Page RCL, Adams CBT, Wass JAH 1999 Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561-567
12. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas. Clin Endocrinol (Oxf.) 49:653-657
13. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
14. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
15. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102-152
16. Bevan JS 2005 The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
17. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, and the participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group 2006 J Endocrinol Invest 29:1017-1020
18. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, Cantore G, Tamburrano G, Cassone R 2001 Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55:307-313
19. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
20. De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A 2007 The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11:13-20
21. Herrington AM, George KW, Moulds CC 1998 Octreotide-induced bradycardia. Pharmacotherapy 18:413-416
22. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ 2005 Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol 187:379-386
23. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L,Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
24. Shibasaki T, Masuda A, Hotta M, Yamauchi N, Hizuka N, Takano K, Demura H, Shizume K 1989 Effects of ingestion of glucose on GH and TSH secretion: evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients. Life Sci 44:431-418
25. Castelli WP 1996 Lipid, risk factors and ischaemic heart disease. Atherosclerosis 124:(Suppl):S1-S9
26. World Health Organization 1999 Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
28. Lamberts SW, de Herder WW, van der Lely AJ 1998 Pituitary insufficiency. Lancet 352:127-134
29. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362
30. Sahn DJ, De Maria A, Kissio J, Weyman A 1978 The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation 58:1072-1083
31. Devereux RB 1987 Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9(Suppl 2):19-26
32. Feigenbaum H 1994 Echocardiography. 5th ed. Philadelphia: Lea and Febiger
33. Melmed S 2006 Acromegaly. N Engl J Med 355:2558-2573
34. Ciric I, Ragin A, Baumgartner C, Pierce D 1997 Complications of transsphenoidal surgery: results of a National survey, review of the literature and personal experience. Neurosurgery 40:225-237
35. Cappabianca P, Cavallo LM, Colao A, de Divitiis E 2002 Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg 97:293-298
36. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473
37. Ben-Shlomo A, Melmed S 2003 The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968
38. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S, the Multicenter Italian Study Group on Lanreotide 2003 Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a single-blind prospective multicenter study. J Endocrinol Invest 25:971-976
39. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G 2003 High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88:3196-3201
40. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM 2006 Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16:101-107
41. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M 2006 Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121-128
42. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G 2007 Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579-587